Day Lila

Biotech · Tuesday, 17 November 2026

Written by AI agents built on Claude, from the sources they cite, and overseen by Zeemish. How it's made

This day: every beat The day in 12 minutes

Swipe 22 stories

Helus's modified psilocybin pill beats a dummy pill in a 222-person depression trial, with 3 serious harms on the drug

22 stories 34 sources

Signals on this beat

Big drugmakers buying startups High ↑
  • Eli Lilly is buying Calytrix Bio, its 15th company purchase this year. [16]
  • Johnson & Johnson is paying $2.2 billion up front for Ollin Biosciences, an eye drug startup. [13]
Money for final-stage trials Building ↑
  • Blackstone Life Sciences will pay $750 million for the final trials of J&J's new eye drug. [15]
  • Sofinnova Partners raised 725 million euros for biotechs close to selling products. [18]
Chinese labs supplying new drugs Building ↑
  • The eye drug J&J is buying was invented by Innovent Biologics in Shanghai. [13]
  • China's two biggest listed drugmakers are each worth nearly $50 billion, a new ranking finds. [19]
US politics reaching into science High ↑
  • In 2026, 8.5% of renewed NIH research grants had their wording changed, against 0.4% in 2023. [24]
  • The FDA proposed a new category that keeps the supplement NAC on sale. [17]

The stories

22 on this beat today.

Each story is told in its parts: what happened, the questions that explain it, how it works, who gains and who pays, and the good news. A part appears when the sources give it.

  1. 01

    Helus's modified psilocybin pill beats a dummy pill in a 222-person depression trial, with 3 serious harms on the drug

    7.6 points

    more fall in depression score on HLP003 than on a dummy pill, at 6 weeks

    analysts had expected 5 to 6 points [1]

    222

    people with major depression in Helus's final-stage trial

    each got 2 doses 3 weeks apart, or a dummy [1]

    39.3% vs 15.5%

    of patients in remission on day 2, drug against dummy

    the gap showed within a day of the first dose [1]

    3

    serious harms linked to treatment on the drug, none on the dummy

    one was a suicide attempt 55 days after the second dose [1]

    What happened

    • Helus Pharma said on 16 November its depression pill HLP003 met the main goal of a final-stage trial. [1]
    • HLP003 is a chemically changed form of psilocybin, the drug in magic mushrooms. [1]
    • The trial gave 222 people with major depression 2 doses, 3 weeks apart, or a dummy pill. [1]
    • After 6 weeks, depression scores fell 19.5 points on the drug and 11.9 points on the dummy. [1][2]
    • The scale, called MADRS, scores symptoms such as sadness, poor appetite and suicidal thoughts. [1]
    • By day 2, 39.3% on the drug were in remission, scoring low enough to count as well. [1] On the dummy, 15.5% were. [1]
    • At 12 weeks the gap held: scores were down 16.9 points on the drug and 9.9 on the dummy. [2]
    • People in the trial took HLP003 or the dummy on top of their usual antidepressants. [1][2]
    • So HLP003 was tested as an add-on to antidepressants, not as a replacement for them. [1]
    • One was a suicide attempt by a patient the drug had not helped, 55 days after the second dose. [1]
    • Two patients left the study on day 2, after their first dose. [1]
    • STAT, a health news site, reports that these harms raised questions about the treatment's safety. [2]
    • Helus swapped some hydrogen atoms in the molecule for deuterium, a heavier form of hydrogen. [1]
    • Fierce Biotech, a trade site, says the change keeps the drug's effects but makes it faster and more predictable. [1]

    Who is involved

    • Compass Pathways a rival making a psilocybin drug for hard-to-treat depression, with a fast-review voucher
    • Usona got a fast-review voucher
    • Helus Pharma a drugmaker developing HLP003, a changed form of psilocybin; it ran the trial and reported the results
    • Jefferies an investment bank whose analysts say the result can compete with approved add-on drugs
    • The FDA the US drug regulator, told in April to speed up reviews of psychedelic drugs; it will rule on HLP003

    How it unfolded

    In April, President Trump ordered the FDA, the US drug regulator, to speed up reviews of psychedelic drugs. [1][3]

    Compass Pathways and Usona then got vouchers for a fast review of their psilocybin drugs. [3]

    Helus was not one of the companies given a voucher. [1]

    In August 2024 the FDA rejected the first psychedelic sent for approval, an MDMA treatment from Lykos Therapeutics. [3]

    1. Second dose 3 weeks after the first
    2. 55 days later a suicide attempt
    3. Aug 2024 the FDA rejects an MDMA treatment from Lykos [3]
    4. This April faster reviews ordered
    5. 16 Nov first trial meets its goal
    6. Late 2027 Helus's second final-stage trial reports [1]
    7. Apr 2026 President Trump orders faster reviews of psychedelic drugs [3]
    8. Jul 2026 Eli Lilly buys AtaiBeckley for $2.8 billion up front [1]
    9. 16 Nov 2026 Helus says HLP003 met its main goal [1]

    Why it matters

    Analysts at Jefferies, an investment bank, say the results look competitive with approved antipsychotic drugs. [1]

    It is the latest result in a wave of psychedelic drugs moving toward approval for depression. [1][4]

    Think it through

    1. 1

      Is a 7.6-point gap a big effect?

      Jefferies had expected a gap of 5 to 6 points, so the result beat its forecast. [1]

      1. 1expected low5 points
      2. 2expected high6 points
      3. 3result7.6 points
    2. 2

      Does that beat Compass's psilocybin drug?

      Compass reported a drop of 3.8 points, on a depression scale running to 60, in its own trial. [4] Its patients had depression other treatments had failed to lift. [4]

    3. 3

      Why is Helus in no hurry?

      Its second final-stage trial reports at the end of 2027. [1] Jefferies says other psychedelic drugs reaching patients first could help its launch. [1]

    4. 4

      Who else is betting on psychedelics?

      Eli Lilly paid $2.8 billion up front for AtaiBeckley, a psychedelic drug maker, in July. [1] Johnson & Johnson already sells Spravato, a ketamine-based depression spray approved in 2019. [3]

    5. 5

      So who decides if HLP003 reaches patients?

      The FDA does, and it will see 3 serious harms beside a 7.6-point gain. [1] Helus's next big piece of evidence is its second trial, due in late 2027. [1]

    How it works

    Medicinal chemists call this deuteration: a heavier atom makes a chemical bond harder for the body to break.

    Helus used deuteration on psilocin, the form of the drug in HLP003, to make it act faster and more predictably. [1]

    Seen it before

    A thicker rope frays more slowly, so you can tell better how long it will hold.

    The truth

    • Every number here comes from Helus's own release and investor call on 16 November. [1] So far the whole case rests on one trial of 222 people. [1]

    What comes next

    Helus's second final-stage trial is due to report in the last quarter of 2027. [1]

  1. 02

    FDA approves Roche's breast cancer pill

    What happened

    • The FDA approved Wilserdly, a breast cancer pill from Roche, the Swiss drugmaker, on 16 November. [5]
    • It is for advanced breast cancer that grows on hormones and has a change in a gene called ESR1. [5]
    • That gene change is a sign the cancer is learning to resist standard treatment. [5]
    • Up to 40% of patients whose cancer of this kind has spread develop the ESR1 change. [6] That figure is from Genentech, Roche's US arm. [6]
    • Wilserdly is taken with everolimus, another pill, so the treatment needs no injections. [6]

    How it unfolded

    Roche has said the drug could become its best-selling product ever, STAT reports. [5]

    1. 16 Nov approved for advanced cancer
    2. By 30 Nov ruling on early cancer

    Why it matters

    Patients whose cancer starts resisting hormone treatment often need harsher treatment, and this adds an option taken by mouth. [6]

    Think it through

    1. 1

      How does the pill fight the cancer?

      It blocks oestrogen from its receptor, the docking point on a cancer cell. [6] It also makes the cell break that receptor down. [6]

    2. 2

      Why does Roche need this drug so much?

      Roche has fallen behind rival drugmakers in cancer drugs in recent years, STAT reports. [5] It hopes Wilserdly will lead a new way of treating the disease. [8]

    3. 3

      So where is the bigger prize?

      In early cancer: over 90% of this type of breast cancer is found at an early stage, Genentech says. [6]

      90 of 100

      over 90 in 100 found early

    How it works

    Cancer pharmacologists call this drug a degrader: it makes the cell destroy its own target, not just block it.

    As a degrader, Wilserdly removes the oestrogen receptor the cancer still depends on after other treatment fails. [6]

    Seen it before

    Taking the batteries out of a remote stops it, even if someone has jammed its buttons.

    Why a trial hides who got the real drug

    Trial designers call it blinding: when patients and doctors cannot tell who got the drug, nobody's hopes can push the score up.

    The twist

    A dummy pill only protects a result while nobody can tell it from the real one.

    Step by step

    1. A score judged by people can be nudged by what they hope
    2. So a trial hides who got the drug, with a dummy pill or a sham device
    3. Patients and doctors then rate everyone the same way
    4. Where hiding is impossible, the trial leans on harder measures or outside judges

    The same force, elsewhere today

    Where this chain is also running, in today's other stories.

    • The Alzheimer's headset

      Cognito tested Spectris against a sham headset, so users could not tell who had the real light and sound.

    • Roche's breast cancer pill

      Its trial was open-label, so the doctors who knew who got Wilserdly also judged when each tumour grew.

    • CG Oncology's bladder drug

      With no dummy treatment, the trial scored a hard event that check-ups can see: the cancer coming back.

    Seen it before

    Orchestra auditions

    players perform behind a screen so judges hear the music, not the person

    Wine tasting

    bottles are hidden so the label cannot sway the score

    Science journals

    reviewers are not told who wrote a paper, so a famous name cannot carry it

    The catch

    Hiding can fail on its own: a drug people can feel may tell them which group they are in.

    And the whole of it

    Everyone who reads a trial result, us included, hopes for the drug too. The people inside the trial cannot see the whole of it, and neither can we.

    The truth

    • The trial was open-label: doctors knew who got Wilserdly, and they also judged when each tumour grew. [6]

    What comes next

    The FDA is due to rule on Wilserdly after surgery for early breast cancer by 30 November. [7]

  1. 03

    A virus drug cuts bladder cancer's return

    What happened

    • CG Oncology said its drug cretostimogene cut the risk of bladder cancer coming back by 68% in a final-stage trial. [9]
    • The trial, PIVOT-006, followed 367 patients for 17 months after surgery removed their tumours. [10]
    • The drug is a common cold virus engineered to infect and burst bladder cancer cells. [11]
    • Doctors pour it into the bladder through a thin tube called a catheter. [11]
    • No patient stopped treatment because of side effects, and none had severe drug-related ones. [9]
    • CG's shares rose 12%, putting its value near $8 billion. [9]

    How it unfolded

    1. Next month full data shown
    2. Mid 2027 approval request

    Why it matters

    When this cancer keeps coming back, some patients end up having the bladder removed. [9]

    Think it through

    1. 1

      What did the other patients get?

      Only the usual check-ups every 3 months after surgery. [11] There was no dummy treatment. [9]

    2. 2

      Did it beat what investors hoped for?

      Yes: CG's managers and investors had hoped for a cut of 30% to 40%, says TD Cowen, an investment bank. [9]

      cut in the risk of the cancer returning
    3. 3

      So who stands to gain, and how much?

      CG does: an RBC analyst estimates US sales of up to $3.2 billion a year by 2035. [9]

      $3.2 billionpossible yearly US sales by 2035

    How it works

    Cancer doctors call this an oncolytic virus: a virus built to multiply inside cancer cells until they burst.

    As an oncolytic virus, cretostimogene kills the cancer cells it enters and also alerts the immune system. [9]

    The idea, in story 02: Why a trial hides who got the real drug →

    The truth

    • Why it works on people One big number is easy to remember: CG called its results "unprecedented" and "unparalleled" a month before showing the full data. [10][9]
    • The 68% comes from CG's own announcement, and the full data come at a medical meeting next month. [9]

    What comes next

    CG plans to ask the FDA to approve it for these patients in the second quarter of 2027. [10]

  2. 04

    Alzheimer's headset misses its main goal

    What happened

    • A headset that flashes light and plays sound to slow Alzheimer's missed its main goal in its largest trial. [12]
    • Over 12 months, users declined no more slowly than people given a sham, a headset that does nothing. [12]
    • Patients with moderate Alzheimer's got no benefit at all, the company's data show. [12]
    • Patients with mild Alzheimer's seemed to decline more slowly, mainly if they used it nearly daily for about 60 minutes. [12]

    Who is involved

    The device, called Spectris, is made by a company called Cognito Therapeutics. [12]

    • Cognito Therapeutics makes Spectris and ran the trial

    Why it matters

    A working headset would offer an option without drugs, while today's Alzheimer's drugs are costly and carry safety risks. [12]

    Think it through

    1. 1

      Why does Cognito still want approval?

      Its chief executive, Christian Howell, says the mild patients show "a very clear path" to the FDA. [12]

    2. 2

      How does the company explain the miss?

      Howell blames the moderate patients, in whom the headset had no effect. [12]

    3. 3

      So who decides whether mild patients get it?

      The FDA: Cognito plans to ask it for approval on the mild-patient signal. [12]

    How it works

    Trial statisticians call a result in only part of the patients a subgroup finding: a lead, not proof.

    Spectris failed in all patients together, so its mild-patient result is a subgroup finding. [12]

    Seen it before

    A coin that lands heads more at one end of a table is not proved lucky.

    The idea, in story 02: Why a trial hides who got the real drug →

    The truth

    • What is really going on Helus released its trial numbers itself, CG Oncology shows its full data only next month, and Cognito's headset results are data the company provided. [1][9][12]
    • The results come from data the company provided, shown at an Alzheimer's conference on 16 November. [12]
  3. 05

    J&J pays $2.2 billion for an eye drug

    What happened

    • Johnson & Johnson will buy Ollin Biosciences, a biotech startup, for $2.2 billion up front. [13]
    • It may pay $1.1 billion more if the drug hits goals, up to about $3.3 billion in all. [13]
    • Ollin's drug, OLN324, is for wet macular degeneration and diabetic eye swelling, two diseases that damage the retina. [13][15]
    • Blackstone Life Sciences, an investment firm, will pay $750 million to fund the drug's final-stage trials. [15]

    How it unfolded

    The drug was invented by Innovent Biologics, a drugmaker in Shanghai. [13]

    1. Now deal announced
    2. Dec 2028 final trials finish

    Why it matters

    J&J's eye business now sells mostly contact lenses and surgical equipment, so this is a step into eye medicines. [13]

    Think it through

    1. 1

      Who is J&J taking on?

      Roche, whose best-selling eye drug Vabysmo grips the same 2 proteins. [14]

    2. 2

      Why pay so much before the final trials?

      In a small early trial, OLN324 improved vision faster and more than Vabysmo did, Fierce Biotech reports. [14]

    3. 3

      So who is betting most on the trials?

      Blackstone pays the $750 million testing bill. [15] It is repaid through milestone payments and a small share of sales. [14]

    How it works

    Drug strategists call a new drug for a proven target a best-in-class bet: it must beat the leader.

    OLN324 is J&J's best-in-class bet, so its final trials pit it against Eylea and Lucentis, two older eye drugs. [14]

    Seen it before

    A new phone with the same features as the best seller only sells if it does them better.

    The truth

    • An RBC analyst says the price "appears high" and that it is unclear how different the drug is. [13]

    What comes next

    All 4 final trials are due to finish their main phase in December 2028. [14]

  4. 06

    Lilly makes its 15th purchase of the year

    What happened

    • Eli Lilly will pay up to $1.5 billion for Calytrix Bio, a startup making drugs for rare blood cancers. [16]
    • These cancers, myeloproliferative neoplasms, make the body overproduce blood cells, causing bone marrow scarring and clots. [16]
    • Calytrix did not say how much of the price is paid up front. [16]
    • Lilly has spent over $30 billion buying companies this year. [16]

    Why it matters

    Today's drugs for these cancers, such as Jakafi, mainly manage symptoms, Calytrix says. [16]

    Think it through

    1. 1

      How far ahead of its rivals is Lilly?

      This is Lilly's 15th company purchase in 2026, while GSK, Gilead and Novartis have made 3 each. [16]

      company purchases in 2026
    2. 2

      What would this drug do differently?

      It aims at a protein that appears only on cells with a faulty gene called CALR, sparing healthy tissue. [16]

    3. 3

      So who carries the risk in this deal?

      Calytrix's backers, including a venture arm of JP Morgan, get the rest only if the drug passes tests. [16]

    How it works

    Antibody engineers call a drug that grips two separate spots on one protein biparatopic.

    Calytrix's biparatopic drug binds 2 sites on the faulty CALR protein, to hit sick cells and spare healthy ones. [16]

    Seen it before

    Holding a jar with both hands makes it far less likely to slip.

    The truth

    • Calytrix gave no further details of the drug or its targets. [16]
    • Nobody knows yet

      What Calytrix's drug has shown so far.

  5. 07

    The FDA moves to keep NAC on shelves

    What happened

    • The FDA proposed a rule that would let NAC, a widely sold supplement, stay on sale as a supplement. [17]
    • NAC, short for N-acetyl-L-cysteine, is already sold over the counter. [17]
    • FDA rules bar approved drugs from being sold as supplements, which left NAC in a legal grey area. [17]

    How it unfolded

    The FDA approved NAC as a drug in 1963, to break up mucus in some lung diseases. [17]

    In 1985 it was approved again, to treat overdoses of acetaminophen, the painkiller also called paracetamol. [17]

    1. 1963 approved for mucus
    2. 1985 approved for overdoses

    Why it matters

    STAT calls it a win for supplement backers, including the MAHA (Make America Healthy Again) movement. [17]

    Think it through

    1. 1

      Why not just call NAC a supplement?

      Because it was a drug first, and the rules forbid that. [17] So the FDA needs a new category: in effect, not "not a supplement". [17]

    2. 2

      So who gains from the change?

      Supplement backers, STAT says: NAC keeps its place on shop shelves. [17]

    How it works

    Lawyers call it regulatory classification: the label a product gets decides which rules it must follow.

    NAC's 1963 drug approval set its class, so only a new FDA category can move it to the supplement rules. [17]

    The truth

    • It is only a proposed rule so far, not a final one. [17]
    • Nobody knows yet

      Whether the FDA will finalise the new category that keeps NAC on sale.

      The rule is only a proposal so far. [17]

  6. 08

    Europe's Sofinnova raises 725 million euros

    What happened

    • Sofinnova Partners, a European venture firm, raised 725 million euros for biotechs close to selling products. [18]
    • It is the firm's largest fund yet, and it manages about 4 billion euros in all. [18]
    • The new fund has already put money into CellCentric and Hemab Therapeutics for their trials. [18]

    Who is involved

    • Abivax now worth about $7 billion
    • Verona Pharma bought by Merck

    How it unfolded

    Sofinnova backed Abivax, now worth about $7 billion, and Verona Pharma, which Merck later bought. [18]

    Why it matters

    Late-stage European biotechs get a large new source of money for their final trials. [18]

    Think it through

    1. 1

      Why does Europe need this kind of fund?

      Kinam Hong, a Sofinnova partner, says Europe has no shortage of ideas, only of money to grow them. [18]

    2. 2

      Where is other biotech money going?

      Over 70 private rounds this year went to biotechs already testing drugs in people, among 26 investors BioPharma Dive tracks. [18]

      70private rounds for drugs already in human trials

    How it works

    Investors call this a crossover fund: it buys into private companies late and can keep the shares after they list.

    Sofinnova's crossover fund puts money in late so its companies can reach global markets, its chairman says. [18]

    The truth

    • Hong says European drugmakers are wrongly seen as "discount" companies, and the firm aims to change that view. [18]
  7. 09

    A new ranking of China's drugmakers

    What happened

    • STAT and WireScreen, a research firm, ranked China's 25 most valuable listed drugmakers on 16 November. [19]
    • BeOne Medicines, once called BeiGene, came first. [19] Jiangsu Hengrui Pharmaceuticals came second. [19]
    • Each is worth nearly $50 billion. [19]
    • Firms are scored half on stock market value and half on sales. [19]

    Who is involved

    • BeOne Medicines first, sells worldwide
    • Jiangsu Hengrui second, licenses to the West

    How it unfolded

    By 2030, China aims to make at least a quarter of the world's first-in-class drugs, ones working in new ways. [19]

    Why it matters

    Western drugmakers keep buying cheap drug ideas from Chinese labs, STAT reports, as J&J's eye deal shows. [19][13]

    Think it through

    1. 1

      How close are they to the world's biggest drugmakers?

      One Chinese chief executive sets the bar at $50 billion of market value. [20] No listed Chinese drugmaker has reached it. [20]

    2. 2

      What could slow them down?

      Last month the Trump administration moved to block some deals between US firms and Chinese drugmakers. [19]

    3. 3

      So who needs whom more?

      US drugmakers want to keep buying low-cost Chinese inventions. [19] US officials are weighing limits on those purchases. [19]

    How it works

    Economists call this comparative advantage: each side makes what it makes most cheaply and trades for the rest.

    Hengrui's comparative advantage is drugs developed swiftly and efficiently, so Western firms license them. [19]

    The truth

    • The ranking counts value and sales, not whether the medicines work for patients. [19]
    • Nobody knows yet

      How many Chinese-invented drugs Western firms will still be allowed to buy.

      The Trump administration moved to block some deals, and after the midterm elections nobody is sure how US policy will change. [19]

  8. 10

    Cellectis to cut up to 70% of its staff

    What happened

    • Cellectis, a Paris gene-editing company, expects to cut up to 70% of its staff over 2026 and 2027. [21]
    • It began 2026 with 229 full-time workers in Paris, New York and North Carolina. [21]
    • It now works on editing genes inside the body, with 2 drugs not yet tested in people. [21]

    How it unfolded

    In September it dropped its 2 cancer treatments made from donor immune cells, both already in human trials. [21]

    Why it matters

    The cuts need talks with French works councils, the staff bodies a French firm must consult. [21]

    Think it through

    1. 1

      Why drop treatments that were already in trials?

      Cellectis said the market and medical picture for those blood cancers had changed a great deal in 2026. [21]

    2. 2

      So what is the company betting on now?

      Its future rests on 2 drugs tested only in the lab so far. [21]

      2 of 2

      lab-stage drugs

    How it works

    Biotech managers call this a pivot: dropping one technology to put the company's money into another. [21]

    Cellectis calls its pivot to in-body gene editing a realignment, and the job cuts are part of it. [21]

    Seen it before

    A shop that stops selling bikes to sell e-scooters lets its bike mechanics go.

    The truth

    • The cut is "up to" 70%: the final number waits on staff talks and labour law. [21]
  9. 11

    Rezolute's drug wins a small final trial

    What happened

    • Rezolute's drug ersodetug met its main goal in a final-stage trial for tumour hyperinsulinism, Fierce Biotech reports. [22]
    • To join, patients had needed sugar dripped into a vein for at least 7 days. [22]
    • 13 of the 16 patients halved the sugar drip they needed, beating the goal of 9. [22]
    • One patient left early and died a week later as the cancer grew. [22]
    • Rezolute's shares rose 10% in early trading on 13 November. [22]

    Why it matters

    A win here may help Rezolute's case for people born with the condition, analysts at Guggenheim say. [22]

    Think it through

    1. 1

      Why does the inborn form need help?

      Its final trial in people born with the condition missed its goal, so the FDA asked Rezolute to meet first. [22]

    2. 2

      So who decides what comes next?

      The FDA: Rezolute meets its staff in early 2027 with these results. [22]

    How it works

    Doctors who treat hormone diseases call it hyperinsulinism: the body makes too much insulin, the hormone that lowers blood sugar.

    In hyperinsulinism, ersodetug binds the insulin receptor at a side spot, so patients need less sugar dripped in. [22]

    The truth

    • The trial is small: 16 patients, and 3 were still in its main phase. [22]

    Good news

    • 12 patients came off the sugar drip completely. [22]
  10. 12

    Bristol Myers merges its research and trials

    What happened

    • Bristol Myers Squibb, a big US drugmaker, will merge its research and development units on 1 January. [23]
    • Cristian Massacesi, its chief medical officer and head of development, will lead the combined unit. [23]
    • Robert Plenge, its research chief, is leaving, though he will advise the company until March. [23]

    How it unfolded

    1. 1 January units merge
    2. March Plenge's advice ends

    Why it matters

    The person who runs BMS's trials will now also run the labs that find its new drugs. [23]

    Think it through

    1. 1

      Why join the two halves?

      Chief executive Christopher Boerner says the old line between research and development is collapsing. [23] He says one unit will attract talent and use new technology better. [23]

    2. 2

      So who loses a seat?

      The research chief does: Plenge's post goes as his unit joins development. [23]

    How it works

    Management scholars call this a reorganisation: changing who reports to whom, to change how decisions get made.

    In BMS's reorganisation, the research labs will report to Massacesi, the head of trials. [23]

    The truth

    • The only reasons on record are Boerner's own: talent, skills and new technology. [23]
  11. 13

    An HIV study loses its cash payments

    What happened

    • An HIV scientist says US health officials made her strip cash payments out of a study they had approved. [24]
    • Jade Pagkas-Bather planned to test whether $500 a month helped poor, HIV-positive young people in Chicago keep up treatment. [24]
    • She was told to drop the cash or find $1 million elsewhere for her $1.3 million grant. [24]
    • She swapped the cash for food and transport vouchers. [24]

    Who is involved

    • The NIH funds US medical research

    How it unfolded

    The NIH, the US government's medical research funder, approved her first grant in June 2025. [24]

    Why it matters

    Every volunteer must be asked to consent again, because the study they joined has changed. [24]

    Think it through

    1. 1

      Is this one case or many?

      In 2023, 0.4% of renewed NIH grants changed their wording. [24] In 2026, 8.5% did, Grant Witness, an independent tracker, counts. [24]

      share of renewed NIH grants whose wording changed
    2. 2

      Which grants are hit hardest?

      HIV grants: 20.8% of them changed in 2026, against 8.5% of all grants. [24]

      share of renewed grants changed in 2026
    3. 3

      So who can stop it?

      A court: a hearing this month decides whether her lawsuit can speak for many scientists. [24]

    How it works

    Lawyers call it viewpoint discrimination: a government treating speech differently because of the ideas in it. [24]

    Her lawsuit says NIH's rewording of grants is viewpoint discrimination, barred by the US First Amendment. [24]

    The truth

    • NIH says renegotiation is a normal process, and that every changed grant is checked by human experts. [24]
    • Nobody knows yet

      Whether US courts will treat the NIH's grant rewording as censorship.

      A federal court hearing this month decides whether the scientists' lawsuit can speak for many researchers. [24]

  12. 14

    Swiss Ebola patient recovers in Geneva

    What happened

    • A Swiss woman with the Ebola strain spreading in Congo has recovered and left hospital in Geneva. [25]
    • She is the wife of a Swiss embassy worker in Abuja, Nigeria's capital, and was flown out on 26 October. [25]
    • She left hospital on 12 November, the hospital's spokesman told AFP, a news agency. [25]
    • Her husband never had symptoms, and his quarantine ended on 4 November. [25]

    How it unfolded

    1. 26 Oct flown to Geneva
    2. 12 Nov leaves hospital

    Why it matters

    No vaccine or specific drug exists for this strain, called Bundibugyo. [25]

    Think it through

    1. 1

      How deadly has this strain been?

      Since May, it has infected over 11,000 people in Congo and killed over 5,400. [25]

      Congo's Bundibugyo outbreak since May
    2. 2

      So what did her doctors actually give her?

      Supportive care: fluids and treatment of complications as they came, the hospital says. [25]

    How it works

    Doctors call it supportive care: keeping the body going while its own defences fight the virus.

    With no drug for Bundibugyo, Geneva's doctors gave her supportive care until she recovered. [25]

    The truth

    • Her recovery is one patient cared for far from the outbreak, which has also reached Uganda and Kenya. [25]

    Good news

    • A Swiss woman who caught the Bundibugyo strain of Ebola, for which no vaccine or specific drug exists, recovered in a Geneva hospital and went home on 12 November.
  13. 15

    120 men treated with focused ultrasound

    What happened

    • Over 120 men with prostate cancer have been treated with focused ultrasound at Northampton General Hospital in England. [26]
    • The treatment is not widely available on the NHS, Britain's health service. [26]
    • It treats only the part of the prostate that has cancer, not the whole gland. [26]
    • Lance Smith, a patient from Wollaston, was told he was cancer-free in January. [26]

    How it unfolded

    The hospital bought the machine last year after a fundraising campaign. [26]

    Why it matters

    Men treated this way have fewer problems with urination and sex, says consultant Chandran Tanabalan. [26]

    Think it through

    1. 1

      Why not treat the whole prostate?

      Surgery treats the whole prostate, while focal therapy spares the healthy tissue, Tanabalan says. [26]

    2. 2

      So who can get it?

      Men near Northampton, and others who travel there, because few NHS hospitals offer it. [26]

    How it works

    Cancer doctors call it focal therapy: treating only the tumour inside an organ and leaving the rest working.

    Northampton's focal therapy aims high-intensity focused ultrasound at the cancer cells and preserves the rest of the tissue. [26]

    Seen it before

    Cutting the bruise out of an apple saves the rest of the apple.

    The truth

    • The results come from the hospital's consultant and one patient, not from a published trial. [26]

    Good news

    • At Northampton General Hospital in England, over 120 men with prostate cancer have been treated with focused ultrasound that spares healthy tissue, and one, Lance Smith, was told in January he was cancer-free.
  14. 16

    Hormone therapy, genes and thinking

    What happened

    • Hormone therapy after menopause helped thinking skills in some women, depending on their genes and the hormone used. [27]
    • Mateja Perovic of the University of Toronto analysed health data from over 14,000 women past menopause. [27]
    • APOE e4 is a gene version that raises Alzheimer's risk. [27] In its carriers, estradiol helped more than a hormone mix called conjugated estrogens. [27]
    • More than a quarter of people carry 1 or 2 copies of APOE e4. [27]

    How it unfolded

    The work was shown at Neuroscience 2026, the Society for Neuroscience's yearly meeting. [28]

    Why it matters

    About 2 in 3 people diagnosed with Alzheimer's are women. [27]

    Think it through

    1. 1

      Why have past studies disagreed?

      Perovic says hormone therapy is "often thought of as one thing", though there are many types. [27]

    2. 2

      Is there a best time to start?

      Stephanie Perez of UT San Antonio calls midlife a "critical window", from her work in rats. [27]

    How it works

    Pharmacogenomics is the study of how a person's genes change what a drug does in them.

    In Perovic's data, the APOE e4 gene changed which hormone helped: a pharmacogenomic effect. [27]

    Seen it before

    The same shoes fit one friend and blister another, because their feet differ.

    The truth

    • The findings are not yet in a journal. [27] Studies still disagree on whether hormone therapy lowers dementia risk. [27]
  15. 17

    Neanderthal DNA and schizophrenia

    What happened

    • A piece of Neanderthal DNA is linked to a nearly 10% lower risk of schizophrenia in people with 2 copies. [29]
    • The study, in the journal PNAS, used data from the UK Biobank health database. [29]
    • Carriers also had a smaller occipital lobe, the brain area for sight. [29] With 2 copies it was 1.7 cubic centimetres smaller. [29]

    Who is involved

    Paabo won the Nobel Prize in medicine in 2022. [29]

    • Svante Paabo Nobel winner, co-author

    How it unfolded

    Most Neanderthal DNA in people today comes from interbreeding about 47,000 years ago, says co-author Svante Paabo. [29]

    1. 47,000 years ago interbreeding
    2. Today the DNA is still here

    Why it matters

    It shows DNA from an ancient human relative still shapes the brains of people alive today. [29]

    Think it through

    1. 1

      Does it protect against other mental illnesses?

      No: it was not linked to depression, bipolar disorder or ADHD, nor to intelligence. [29]

    2. 2

      How could a gene piece do this?

      It sits near a gene called DAAM1, used in early brain growth, but how they interact is unclear. [29]

    How it works

    Geneticists call this an association study: they match a DNA variant to health records across many people.

    Here the association study matched the Neanderthal variant to schizophrenia risk and to brain size. [29]

    The truth

    • The study shows a correlation, and how the DNA could lower risk is still unknown. [29]
  16. 18

    A tool that shows CRISPR's wrong edits

    What happened

    • Salk Institute scientists built Superb-seq, a way to see every edit CRISPR, a gene-editing tool, makes in each cell. [30]
    • In 10,000 leukaemia cells, 7 guides led to 43 edit sites, and 36 of them were in the wrong place. [30]
    • The team tested it on 34,000 cells from 3 lab cell lines, and published in Nature Methods. [30]

    Why it matters

    Unwanted edits could make gene therapies unsafe, so the tool could help check them early. [30]

    Think it through

    1. 1

      Why were wrong edits missed before?

      Older tools could not show where edits landed and what they did to the cell at the same time. [30]

    2. 2

      So who needs this most?

      Gene therapy makers, who must show their edits are safe. [30] Labs may also find stray edits coloured past CRISPR findings. [30]

    How it works

    Geneticists call edits in the wrong place off-target: the tool cuts DNA that only looks like its target.

    Superb-seq found 36 off-target edits among 43, and showed how edits changed the cells' gene activity. [30]

    Seen it before

    Two words that look alike on a page get swapped by a careless search-and-replace.

    The truth

    • The tool was tested only in lab-grown cell lines, not in patients. [30]
  17. 19

    CRISPR turns up a gene in autism models

    What happened

    • UCLA scientists used a CRISPR tool to turn up a healthy gene copy in lab-grown human brain tissue modelling autism. [31]
    • In some autism cases one copy of a gene is broken, so the other must do the work of two. [31]
    • The team targeted 2 such genes, CHD8 and SCN2A, in a study in Nature Neuroscience. [31]
    • The tool did not cut DNA: it turned genes up through enhancers, stretches of DNA that boost a gene. [31]

    Why it matters

    About 15% of autism's genetic risk comes from mutations like these, the authors write. [31]

    Think it through

    1. 1

      Did it fix the cells?

      Partly: oversized CHD8 tissue grew smaller in most lines, and SCN2A neurons fired closer to normal. [31]

    2. 2

      How close is a treatment?

      Far off: the first author, George Chen, says there is a lot of work ahead on delivery and timing. [31]

    How it works

    Geneticists call one broken copy haploinsufficiency: half the usual amount of a gene's product is not enough.

    To treat haploinsufficiency, the UCLA team made the working CHD8 and SCN2A copies more active. [31]

    Seen it before

    If one of two lamps in a room breaks, you can turn the other one up.

    The truth

    • It worked in lab-grown human cells and tissue, not yet in any living person. [31]
  18. 20

    Gut bacteria in people over 100

    What happened

    • In people over 100, gut bacteria change more bile acids, a UC San Diego study in Cell Metabolism finds. [32]
    • Bile acids, once changed by bacteria, can steer metabolism, inflammation and the body clock. [32]
    • The human data covered 48 young adults, 107 older adults and 125 people over 100. [32]
    • Old mice given engineered gut bacteria making more of the key enzyme handled insulin better after about 20 weeks. [32]

    Why it matters

    It suggests some gut changes in old age may protect health rather than harm it. [32]

    Think it through

    1. 1

      Does this make people live longer?

      Not shown: the study does not prove the bacteria cause long life in people. [32]

    2. 2

      What else changed in the treated mice?

      By 32 weeks they had less fat, more lean mass and burned more fat for energy. [32]

      32weeks to less fat, more lean mass

    How it works

    Microbiologists call the gut's bacteria the microbiome, and its enzymes change chemicals the body makes.

    In this microbiome work, an enzyme called bile salt hydrolase reshaped the bile acids of old mice. [32]

    The truth

    • The authors call their data on people over 100 "corroborative rather than definitive". [32]
  19. 21

    Where a mouse heart ages first

    What happened

    • Ageing inflammation in mouse hearts gathers around the valves and the root of the aorta, Jackson Laboratory scientists found. [33]
    • The aorta is the big artery the heart pumps blood into. [33]
    • Some markers thought to signal ageing were already there in young hearts. [33]
    • The study appeared in the journal Aging Cell. [33]

    How it unfolded

    Past research mostly studied heart muscle, especially the left ventricle, the main pumping chamber. [33]

    Why it matters

    Age is the biggest single risk for heart disease, so knowing where ageing starts can guide research. [33]

    Think it through

    1. 1

      Why do markers in young hearts matter?

      They mean those markers alone cannot show a cell is ageing, says Nadia Rosenthal, the lab's scientific director. [33]

    2. 2

      Do male and female hearts age alike?

      No: in male mice, ageing scar-making cells leaned more toward scarring. [33]

    How it works

    Biologists call ageing's slow, steady inflammation inflammaging. [33]

    In these hearts, inflammaging ran through immune cells and scar-making cells around the valves, more than in the muscle. [33]

    The truth

    • This was in mice, and the study does not show human hearts age the same way. [33]
  20. 22

    A smaller protein that heals eye scars in mice

    What happened

    • University of Houston scientists designed miniDec, a small lab-made copy of decorin, a protein that limits scarring. [34]
    • Full decorin is hard to make in bulk, but miniDec can be grown in E. coli bacteria. [34]
    • Put on the eyes of mice burned with alkali, it cleared clouding and sped healing. [34]
    • It worked about as well as full decorin at the doses tested. [34]

    Why it matters

    Cheap bulk production is what full decorin lacks, so this aims at the main hurdle to using it. [34]

    Think it through

    1. 1

      How does it stop scarring?

      It docks onto TGF-beta1, a signal that drives scarring, and stops cornea cells turning scar-forming. [34]

    2. 2

      So who would own it?

      The University of Houston has filed a US patent application on it. [34]

    How it works

    Protein engineers call this a mimetic: a simpler molecule built to copy the working part of a natural one.

    As a mimetic, miniDec keeps the decorin parts that grip TGF-beta1 and drops the sugars that slow manufacturing. [34]

    The truth

    • It was tested only in mice and in human cells in a dish. [34]

Across the day

What is true of the whole day.

The truth, across the day

  • Several of the day's biggest results come straight from the companies, before outside experts have seen the full data.

Across the beats